Profile data is unavailable for this security.
About the company
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.
- Revenue in HKD (TTM)1.50bn
- Net income in HKD-1.71bn
- Incorporated2008
- Employees3.50k
- LocationRemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
- Phone+86 5 353573685
- Fax+86 5 356113517
- Websitehttp://www.remegen.cn/
More ▼
27.84%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 30 Jun 2024 | 10.88m | 5.74% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 9.90m | 5.22% |
| E Fund Management Co., Ltd.as of 18 Jun 2024 | 9.16m | 4.83% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 5.75m | 3.04% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 5.40m | 2.85% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2024 | 3.22m | 1.70% |
| Schroder Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 2.52m | 1.33% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 2.18m | 1.15% |
| CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 2024 | 2.14m | 1.13% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 1.63m | 0.86% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
